Oncology Peer Review On-The-Go: Current Treatments in Marginal Zone Lymphoma

News
Podcast

Juan Pablo Alderuccio, MD, spoke with CancerNetwork® about a review article on the treatment of marginal zone lymphoma published in the journal ONCOLOGY®.

Juan Pablo Alderuccio, MD, assistant professor of Medicine in the Division of Hematology, Department of Medicine at the Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine in Florida, spoke with CancerNetwork® about his review published in the journal ONCOLOGY® titled, Current Treatments in Marginal Zone Lymphoma.

In the article, Alderuccio explored current approaches to the diagnosis and treatment of marginal zone lymphoma. He also touched on his strategies for treating localized vs advanced disease and novel emerging strategies clinicians who are practicing in the community should be aware of.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
Patients with mantle cell lymphoma who are older and have less fitness may be eligible for regimens that include bendamustine/rituximab.
It may be critical to sequence BCL-2 inhibitors with BTK inhibitors for patients with mantle cell lymphoma in the relapsed/refractory setting.
Reducing the manufacturing time of CAR T-cell therapy may have a big impact on the treatment of patients with mantle cell lymphoma.
Related Content
Boston’s Best Did Not “Leave the Cannoli” in Battle of Lymphoma Top Trials

Boston’s Best Did Not “Leave the Cannoli” in Battle of Lymphoma Top Trials

ONCOLOGY Staff
September 25th 2025
Article

Two teams of lymphoma experts engage in a face-off competition, showcasing real-world updates, patient cases, and use of ASCT or CAR T-cell therapy.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Regarding safety, treatment-related adverse effects occurred in 93% of patients, with grade 3 or 4 TRAEs occurring in 60%.

Mosunetuzumab Treatment Combo Yields Responses in High-Risk MCL

Tim Cortese
September 21st 2025
Article

Michael Wang, MD, stated that results from this phase 2 trial were tremendous and showed that mosunetuzumab plus polatuzumab vedotin is viable in MCL.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 11th 2025
Article

Results from the SUNMO trial showed that mosunetuzumab plus polatuzumab vedotin achieved a complete response rate of 51.4% in this LBCL population.

The overall safety profile of pirtobrutinib was consistent with previously reported trials across various CLL and SLL settings.

Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions

Tim Cortese
September 8th 2025
Article

Results from the phase 3 BRUIN CLL-313 trial show that OS trended favorably for pirtobrutinib vs chemoimmunotherapy in this CLL and SLL population.